Platelet function inhibitors

Citations 191-200 of 249 total displayed.

Past content (since Oct 2000):

Clinical Investigations and Reports Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction: Results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial: Marc A. Brouwer, Paul J.P.C. van den Bergh, Wim R.M. Aengevaeren, Gerrit Veen, Hans E. Luijten, Don P. Hertzberger, Ad J. van Boven, Ralf P.J.W. Vromans, Gérard J.H. Uijen, and Freek W.A. Verheugt
Circulation 2002;106:659-665; published online before print as doi:10.1161/01.CIR.0000024408.81821.32 [Abstract] [Full text]

Current Perspectives
Platelet Glycoprotein IIb/IIIa Inhibitors: Recognition of a Two-Edged Sword?: Martin J. Quinn, Edward F. Plow, and Eric J. Topol
Circulation 2002;106:379-385, doi:10.1161/01.CIR.0000019581.22812.B2 [Full text]

Articles Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction. Results of the Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis (APRICOT)-2 Trial: Marc A. Brouwer, Paul J.P.C. van den Bergh, Wim R.M. Aengevaeren, Gerrit Veen, Hans E. Luijten, Don P. Hertzberger, Ad J. van Boven, Ralf P.J.W. Vromans, Gérard J.H. Uijen, and Freek W.A. Verheugt
Circulation published July 15, 2002, doi:10.1161/01.CIR.0000024408.81821.32 [Abstract]

Clinical Investigations and Reports
Abciximab Attenuates Coronary Microvascular Endothelial Dysfunction After Coronary Stenting: Eve D. Aymong, Michael J. Curtis, Mostafa Youssef, Michelle M. Graham, Lana Shewchuk, Wendy Leschuk, and Todd J. Anderson
Circulation 2002;105:2981-2985; published online before print as doi:10.1161/01.CIR.0000019905.18467.07 [Abstract] [Full text]

Clinical Investigations and Reports Impact of Different Platelet Glycoprotein IIb/IIIa Receptor Inhibitors Among Diabetic Patients Undergoing Percutaneous Coronary Intervention: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-Year Follow-Up: Marco Roffi, David J. Moliterno, Bernhard Meier, Eric R. Powers, Cindy L. Grines, Peter M. DiBattiste, Howard C. Herrmann, Michel Bertrand, Katherine E. Harris, Laura A. Demopoulos, Eric J. Topol for the TARGET Investigators*
Circulation 2002;105:2730-2736; published online before print as doi:10.1161/01.CIR.0000018123.02672.C7 [Abstract] [Full text]

Articles
Abciximab Attenuates Coronary Microvascular Endothelial Dysfunction After Coronary Stenting: Eve D. Aymong, Michael J. Curtis, Mostafa Youssef, Michelle M. Graham, Lana Shewchuk, Wendy Leschuk, and Todd J. Anderson
Circulation published May 28, 2002, doi:10.1161/01.CIR.0000019905.18467.07 [Abstract]

Correspondence
Activating Effects of GPIIb/IIIa Blockers: An Intrinsic Consequence of Ligand- Mimetic Properties • Response: K. Peter, M. Schwarz, C. Bode, Andrew L. Frelinger, III, Mark I. Furman, Lori A. Krueger, Marc R. Barnard, and Alan D. Michelson
Circulation 2002;105:e180-181e, doi:10.1161/01.CIR.0000017280.72394.1F [Full text]

Basic Science Reports Functional Significance of Adenosine 5'-Diphosphate Receptor (P2Y₁₂) in Platelet Activation Initiated by Binding of von Willebrand Factor to Platelet GP Ib ${alpha}$ Induced by Conditions of High Shear Rate: Shinya Goto, Noriko Tamura, Koji Eto, Yasuo Ikeda, and Shunnosuke Handa
Circulation 2002;105:2531-2536; published online before print as doi:10.1161/01.CIR.0000016703.93845.AF [Abstract] [Full text]

Clinical Investigations and Reports Impact of Clinical Syndrome Acuity on the Differential Response to 2 Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Coronary Stenting: The TARGET Trial*: Gregg W. Stone, David J. Moliterno, Michel Bertrand, Franz-Josef Neumann, Howard C. Herrmann, Eric R. Powers, Cindy L. Grines, Jeffrey W. Moses, David J. Cohen, Eric A. Cohen, Marc Cohen, Kathy Wolski, Peter M. DiBattiste, and Eric J. Topol
Circulation 2002;105:2347-2354; published online before print as doi:10.1161/01.CIR.0000017635.82128.8C [Abstract] [Full text]

Clinical Investigations and Reports Benefits and Safety of Tirofiban Among Acute Coronary Syndrome Patients With Mild to Moderate Renal Insufficiency: Results From the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Trial: James L. Januzzi, Jr, Steven M. Snapinn, Peter M. DiBattiste, Ik-Kyung Jang, and Pierre Theroux
Circulation 2002;105:2361-2366; published online before print as doi:10.1161/01.CIR.0000016359.94919.16 [Abstract] [Full text]

Subspecialty Collections Home

Show Platelet function inhibitors
collections from other journals.